The '4+7' varieties fell below the winning price

Recently, the Guangdong Provincial Drug Trading Center announced the "Notice of the First Drug Auction Transaction Results in 2019", which announced the first drug auction transaction results in Guangdong Province in 2019. The notice shows that the transaction prices of several drugs have been lower than the previous quotations of the first round of "4+7" selected pharmaceutical enterprises, such as clopidogrel (75mg) of Shih Pharmaceutical Group, olanzapine tablets (10mg) of Qilu Pharmaceutical, escitalopram tablets (10mg) of Zhejiang Kang'anbei. Specifically, the clopidogrel tablets (75mg) of Shih Pharma Group Ouyi Pharmaceutical and the "4+7" selected manufacturer Shenzhen Xinlitai have passed the consistency evaluation of generic drugs.

The unit price of Shih Pharma's clopidogrel tablets (75mg) was as low as RMB 3.0153 in Guangdong Province, which is 5.18% lower than the selected unit price of RMB 3.18 for Shenzhen Xinlitai. In addition, Qilu Pharmaceutical's olanzapine tablets (10mg) have passed the generic drug consistency evaluation, and in the first drug bidding transaction in Guangdong Province in 2019, the price was reduced to 5.7 yuan per unit, which is lower than the price of 9.6443 yuan for the smallest unit of olanzapine tablets of Jiangsu Haosen Pharmaceutical, the selected pharmaceutical company of "4+7", by The price of the smallest unit of olanzapine tablet of Jiangsu Haosen Pharmaceuticals is 9.6443 yuan, which is 40.9% lower. Also Qilu Pharmaceutical, in the first round of "4 + 7" drug collection, gefitinib tablets (0.25g) finally by the original pharmaceutical company AstraZeneca to unit price of 54.7 won the bid. This time, Qilu Pharmaceutical (Hainan) Co., Ltd. offered a unit price of 49.8 in Guangdong Province, which is 8.96% lower than AstraZeneca's "4+7" winning price.